Erratum: Effects of Zinc Supplementation on Markers of Insulin Resistance and Lipid Profiles in Women with Polycystic Ovary Syndrome: a Randomized, Double-blind, Placebo-controlled Trial (Exp Clin Endocrinol Diabetes (2015) 123 DOI 10.1055/s-0035-1548790);Effects of zinc supplementation on markers of insulin resistance and lipid Profiles in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial

Experimental and Clinical Endocrinology and Diabetes

Volumn 123, Issue 4, 2015, Pages 215-220

  Foroozanfard, F ^a   Jamilian, M ^b   Jafari, Z ^a   Khassaf, A ^a   Hosseini, A ^a   Khorammian, H ^a   Asemi, Z ^a  

^a KASHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

insulin metabolism; lipid concentrations; polycystic ovary syndrome; supplementation; zinc

Indexed keywords

GLUCOSE; INSULIN; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ZINC; ZINC SULFATE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; LIPID;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; TRIACYLGLYCEROL BLOOD LEVEL; ZINC BLOOD LEVEL; ADOLESCENT; BLOOD; DIET SUPPLEMENTATION; METABOLISM; PHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; BLOOD GLUCOSE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; POLYCYSTIC OVARY SYNDROME; TREATMENT OUTCOME; YOUNG ADULT; ZINC SULFATE;

EID: 84927631683     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/a-1736-9518     Document Type: Erratum

References (31)

1. Kabil Kucur S., Gozukara I., Aksoy A. et al. How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome? Blood Coagul Fibrinolysis: 2014; [Epub ahead of print]
2. Tosi F., Di Sarra D., Kaufman J. M. et al. Total body fat and central fat mass independently predict insulin resistance but not hyperandrogenemia in women with polycystic ovary syndrome. J Clin Endocrinol Metab: 2014; jc20142786
3. Mehrabian F., Khani B., Kelishadi R. et al. The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females. J Res Med Sci: 2011; 16 763 769
4. Dokras A., Bochner M., Hollinrake E. et al. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol: 2005; 106 131 137
5. Wild S., Pierpoint T., McKeigue P. et al. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf): 2000; 52 595 600
6. Cassar S., Teede H. J., Harrison C. L. et al. Biomarkers and insulin sensitivity in women with PCOS: Characteristics and predictive capacity. Clin Endocrinol (Oxf): 2014; 10.1111/cen.12619 [Epub ahead of print]
7. Johnson N. P. Metformin use in women with polycystic ovary syndrome. Ann Transl Med: 2014; 2 56
8. Kelishadi R., Hashemipour M., Adeli K. et al. Effect of zinc supplementation on markers of insulin resistance, oxidative stress, and inflammation among prepubescent children with metabolic syndrome. Metab Syndr Relat Disord: 2010; 8 505 510
9. Song Y., Wang J., Li X. K. et al. Zinc and the diabetic heart. Biometals: 2005; 18 325 332
10. Partida-Hernandez G., Arreola F., Fenton B. et al. Effect of zinc replacement on lipids and lipoproteins in type 2-diabetic patients. Biomed Pharmacother: 2006; 60 161 168
11. Marreiro D. N., Geloneze B., Tambascia M. A. et al. Effect of zinc supplementation on serum leptin levels and insulin resistance of obese women. Biol Trace Elem Res: 2006; 112 109 118
12. Khan M. I., Siddique K. U., Ashfaq F. et al. Effect of high-dose zinc supplementation with oral hypoglycemic agents on glycemic control and inflammation in type-2 diabetic nephropathy patients. J Nat Sci Biol Med: 2013; 4 336 340
13. Beletate V., El Dib R. P., Atallah A. N. Zinc supplementation for the prevention of type 2 diabetes mellitus. Cochrane Database Syst Rev: 2007; CD005525
14. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril: 2004; 81 19 25
15. Ramezani Tehrani F., Minooee S., Azizi F. Validation of a simplified method to assess hirsutism in the Iranian population. Eur J Obstet Gynecol Reprod Biol: 2014; 174 91 95
16. Pisprasert V., Ingram K. H., Lopez-Davila M. F. et al. Limitations in the Use of Indices Using Glucose and Insulin Levels to Predict Insulin Sensitivity: Impact of Race and Gender and Superiority of the Indices Derived From Oral Glucose Tolerance Test in African Americans. Diabetes Care: 2013; 36 845 853
17. Kim J., Lee S. Effect of zinc supplementation on insulin resistance and metabolic risk factors in obese Korean women. Nutr Res Pract: 2012; 6 221 225
18. Hashemipour M., Kelishadi R., Shapouri J. et al. Effect of zinc supplementation on insulin resistance and components of the metabolic syndrome in prepubertal obese children. Hormones (Athens): 2009; 8 279 285
19. Bargiota A., Diamanti-Kandarakis E. The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Adv Endocrinol Metab: 2012; 3 27 47
20. Guler I., Himmetoglu O., Turp A. et al. Zinc and homocysteine levels in polycystic ovarian syndrome patients with insulin resistance. Biol Trace Elem Res: 2014; 158 297 304
21. Chakraborty P., Ghosh S., Goswami S. K. et al. Altered trace mineral milieu might play an aetiological role in the pathogenesis of polycystic ovary syndrome. Biol Trace Elem Res: 2013; 152 9 15
22. Adachi Y., Yoshikawa Y., Sakurai H. Antidiabetic zinc(II)-N-acetyl-L-cysteine complex: evaluations of in vitro insulinomimetic and in vivo blood glucose-lowering activities. Biofactors: 2007; 29 213 223
23. Gomez-Garcia A., Hernandez-Salazar E., Gonzalez-Ortiz M. et al. Effect of oral zinc administration on insulin sensitivity, leptin and androgens in obese males. Rev Med Chil: 2006; 134 279 284
24. Wijesekara N., Chimienti F., Wheeler M. B. Zinc a regulator of islet function and glucose homeostasis. Diabetes Obes Metab: 2009; 11 04 202 214
25. Wiernsperger N., Rapin J. Trace elements in glucometabolic disorders: an update. Diabetol Metab Syndr: 2010; 2 70 10.1186/1758-5996-2-70
26. Stamatiadis D., Bulteau-Portois M. C., Mowszowicz I. Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol: 1988; 119 627 632
27. Payahoo L., Ostadrahimi A., Mobasseri M. et al. Effects of zinc supplementation on the anthropometric measurements, lipid profiles and fasting blood glucose in the healthy obese adults. Adv Pharm Bull: 2013; 3 161 165
28. Hooper P. L., Visconti L., Garry P. J. et al. Zinc lowers high-density lipoprotein-cholesterol levels. JAMA: 1980; 244 1960 1961
29. Hughes S., Samman S. The effect of zinc supplementation in humans on plasma lipids, antioxidant status and thrombogenesis. J Am Coll Nutr: 2006; 25 285 291
30. Rogalska J., Brzoska M. M., Roszczenko A. et al. Enhanced zinc consumption prevents cadmium-induced alterations in lipid metabolism in male rats. Chem Biol Interact: 2009; 177 142 152
31. Petering H. G., Murthy L., O'Flaherty E. Influence of dietary copper and zinc on rat lipid metabolism. J Agric Food Chem: 1977; 25 1105 1109